MedTrace Logo

Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma

NCT01747642 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-12-12

No results posted yet for this study

Summary

Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)

Conditions

  • Quality of Life

Interventions

DIETARY_SUPPLEMENT

Oncoxin

Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days

DRUG

Suranix

Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days

Sponsors & Collaborators

  • Clinical Research Organization, Dhaka, Bangladesh

    lead OTHER

Principal Investigators

  • Mamun A Mahtab, MD, FACG · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-12-31
Completion
2014-06-30

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01747642 on ClinicalTrials.gov